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Purpose: To assess 25-hydroxyvitamin D -25(OH)D- status in Spanish adult subjects, 
and to analyze its relationships with serum PTH levels, calcium intake and bone mineral 
density (BMD). 
Methods: A total of 1811 individuals (1154 postmenopausal women and 657 men) aged 
44-93 years participated in the study. Serum 25(OH)D, intact parathyroid hormone 
(PTH), aminoterminal propeptide of type I collagen (P1NP), and C-terminal telopeptide 
of type I collagen (β-CTX) levels, were measured by electrochemiluminescence. BMD 
was determined by dual X-ray absorptiometry (DXA) at lumbar spine, femoral neck and 
total hip. 
Results: Serum 25(OH)D levels were below 10, 20 and 30 ng/ml in 5%, 40%, and 83% 
of participants, respectively. There was a significant seasonal difference in mean serum 
25(OH)D, with higher levels in summer-autumn. In multivariate analysis, 25(OH)D 
levels were negatively correlated with age, serum PTH and creatinine, body mass index, 
smoking, alcohol intake, and number of chronic diseases, but positively with dairy 
calcium intake. The magnitude of the difference in serum PTH according to 25(OH)D 
quartiles was not influenced by calcium intake. A threshold of serum 25(OH)D around 
30 ng/ml was observed for serum PTH and hip BMD. 
Conclusions: Vitamin D insufficiency is very common among Spanish community-
dwelling adult subjects. A threshold of serum 25(OH)D around 30 ng/ml would be 
necessary for the prevention of secondary hyperparathyroidism and hip bone loss in our 
population, regardless of the dairy calcium ingestion. Programs to improve vitamin D 







































































Vitamin D insufficiency was very common among Spanish community-dwelling adult 
subjects. A threshold of serum 25(OH)D around 30 ng/ml would be necessary for the 
prevention of secondary hyperparathyroidism and hip bone loss in our population, 





































































Vitamin D deficiency is extremely common among elderly subjects. It causes 
secondary hyperparathyroidism, high bone turnover, bone loss, mineralization defects, 
and fractures, and it has also been associated to a number of other conditions, such as 
impaired muscle function and some tumours (1). Since vitamin D3 is synthesized in the 
skin under the influence of UV irradiation, vitamin D status depends on latitude, so 
people living in sunny countries are at lower risk. However, previous studies (2,3) and 
more recent surveys (4-6) among people from different European countries, have shown 
that the greatest incidence of hypovitaminosis D occurs in the Mediterranean area. 
An inverse association between serum 25-hydroxyvitamin D -25(OH)D- and 
serum parathyroid hormone (PTH) is well established, up to a certain level of 25(OH)D, 
in which little further decrease in serum PTH is observed. The serum level of 25(OH)D 
at which PTH becomes constant has been used to identify the lower desirable 
concentration of serum 25(OH)D. Estimates of threshold levels of 25(OH)D varies 
greatly from 8 to 44 ng/ml (6,7,8). This wide range may be due, in part, to different 
methods for measuring both serum PTH and 25(OH)D levels (6,9), and possibly also 
due to different characteristics of the studied populations (10). Previous studies suggest 
that the relationship between PTH and 25(OH)D is modulated by both age and calcium 
intake (11,12). However, other environmental (latitude, season, clouds) and personal 
factors (skin type, age, clothing, renal function, number of chronic diseases, etc.) could 
also be taken into account (6,10,12,13).  
Therefore, the aim of this study was: i) to describe the 25(OH)D status according 
to season, in Spanish postmenopausal women and men ≥50 years, and ii) to analyze its 






































































Subjects and methods 
Study design and participants 
The study population consists of those men and women included in the Camargo 
Cohort Study. Full details of this cohort study have been previously reported (14,15). 
The cohort was set up with the postmenopausal women and men aged 50 years and 
older attending a primary care center in Northern Spain for medical reasons or for their 
regular health examination, whichever happened first. All participants were white, as 
are more than 95% of people in our region (Cantabria) (43º N latitude). The study was 
approved by the local Ethics Committee, and all subjects gave written informed 
consent.  
At the baseline visit, subjects were interviewed by investigators and all 
participants provided data regarding the risk factors of osteoporosis and fractures using 
a structured questionnaire which included age, race, weight, height, body mass index 
(BMI), personal antecedents of fractures in adulthood (>40 years), history of 
osteoporotic fractures among first-degree relatives, tobacco use, consumption of dairy 
products, alcohol use (g/day), physical exercise, the number of falls in the previous 
year, the presence of chronic diseases (cardiovascular disease, chronic obstructive 
pulmonary disease, stroke, diabetes mellitus, and joint disorders including rheumatoid 
arthritis), and present or past consumption of medications. BMI was defined as weight 
(kg) divided by squared height (m2). Dairy calcium consumption was assessed by a food 
frequency questionnaire (16). Level of education was assessed by asking for the highest 
educational level completed, ranging from none to university. Tobacco smoking was 
assessed as current smoker, or never smoker. Alcohol consumption was defined as >20 
g of alcohol per day. Habitual physical activity was classified as high (moving, walking 




































































reasonable distances, does light housework shopping or equivalent, normal activities of 
day-to-day living but no appreciable exercise), and sedentary (little walking outside 
home, or sits in a chair or lies in bed most of the time). In order to evaluate the seasonal 
variation of serum 25(OH)D, the period July-November represented summer-autumn, 
and the period December-April, winter-spring. The presence of chronic diseases 
(cardiovascular disease, stroke, chronic obstructive pulmonary disease, diabetes 
mellitus, chronic liver diseases, malignant neoplasms, and rheumatoid arthritis) was 
assessed through a detailed questionnaire.  
Participants whose baseline assessment revealed the presence of diseases or 
treatments known to affect bone metabolism, such as osteoporosis, primary 
hyperparathyroidism, hyperthyroidism, serum creatinine >1.7 mg/dl (151 μmol/L), or 
use of bisphosphonates, oestrogen, raloxifene, strontium ranelate, teriparatide, L-
thyroxin, anticonvulsants  or glucocorticoids in the previous 1 year, were excluded from 
the study. Participants on calcium and/or vitamin D supplements were also excluded. 
Biochemical tests 
For each participant, fasting blood samples were collected between 09:00 and 
10:30 h. Serum was divided into 0.5-ml aliquots and stored at -40ºC. Serum total 
calcium (TCa), phosphate, creatinine, albumin, and total alkaline phosphatase were 
measured by standard automated methods in an ADVIA 2400 Chemistry System 
autoanalyser (Siemens, Germany). TCa measurements were corrected for albumin 
concentration (cCa) following a previously published formula (17). Serum 
concentrations of 25(OH)D, intact PTH, P1NP, and β-CTX were determined by a fully 
automated Roche electrochemiluminescence system (Elecsys 2010, Roche Diagnostics, 
GmbH, Mannheim, Germany). The detection limit of serum 25 OHD was 4 ng/ml, its 




































































intact PTH, the detection limit was 6 pg/ml, with a normal range of 15-65 pg/ml. 
Intraassay and interassay CV were 3.4% and 5.9%, respectively. The P1NP limit of 
detection was 5 ng/ml (reference range between 15-78 ng/ml), and its intraassay and 
interassay CV were 3.9% and 4.1%, respectively [14,17].  Intraassay and interassay CV 
for β-CTX were 4.2% and 4.7%, also respectively, and the detection limit was 0.01 
ng/ml (14,15). 
DXA measurements 
BMD was measured by DXA (Hologic QDR 4500, Bedford, MA, USA) at the 
lumbar spine (LS), femoral neck (FN), and total hip (TH) in all the 1811 subjects who 
finally entered the study (see below). In vivo precision was 0.4-1.5% at the different 
measurement sites. Results were expressed as grams per square centimetre. Quality 
control was performed according to the usual standards (18,19). 
Statistical analysis 
Baseline characteristics of the population were calculated for the total sample 
and for men and women separately. All continuous variables were tested for normality. 
Variables non-normally distributed underwent logarithmic transformation before 
statistical analyses. Results were expressed as mean ± SD, median [interquartile range] 
or percentages, as appropriate. Student's t test or Mann-Whitney U-test was used to 
determine the differences between groups for continuous variables, and 2-test for 
categorical variables. Stepwise multiple linear regression analysis was conducted to 
identify independent predictors of serum 25(OH)D levels. Participants were divided 
according to age groups (< 60; 60-75; >75 years), serum 25(OH)D quartiles (<17; 17-
22; 22-28; >28 ng/ml) and dairy calcium intake tertiles (<450; 450-700; >700 mg/day). 




































































applying the Bonferroni method for multiple comparisons. A multivariable general 
lineal model, adjusted for potential confounders (age, sex, BMI, level of education, 
exercise, alcohol use, smoking, number of chronic diseases, serum creatinine, and 
season of vitamin D determination), was used to compare mean values of the main 
variables across quartiles of serum 25(OH)D. Finally, locally weighted regression 
smoothing (LOESS) plots, also adjusted for the same confounders, were performed to 
analyze the relationship between serum 25(OH)D levels and various outcome measures. 
A p value <0.05 was considered statistically significant in all the calculations.  
 
RESULTS 
A total of 2308 individuals (1573 postmenopausal women with no menses for at 
least 12 months, and 735 men ≥50 years) were recruited. Of them, 497 were excluded 
because their baseline study revealed the presence of diseases or treatments known to 
affect bone metabolism, or even treatments addressed to bone metabolic diseases, 
including osteoporosis, as well as calcium and/or vitamin D supplements. The 
remaining 1811 subjects (1154 women and 657 men) were entered into the study. 
Epidemiological characteristics, as well as biochemical, and BMD results of the study 
population are showed in Table 1. Serum 25(OH)D was significantly higher in men than 
in women, whereas mean PTH levels did not differ. Serum P1NP and β-CTX 
concentrations were higher in women than in men. Conversely, BMD was significantly 
higher in men than in women. There was a non-significant negative correlation between 
serum 25(OH)D and  P1NP (r= -0.005; p=0.84) or β-CTX (r= -0.01; p=0.68). 
The distribution of participants according to various serum 25(OH)D cut-offs 
was as follows: 5% of subjects had serum levels of 25(OH)D <10 ng/ml, 40% <20 




































































in mean serum 25(OH)D, with a higher level in summer-autumn (26.2±8.3 ng/ml) than 
in winter-spring (20.4±7.6 ng/ml; p<0.0001).  
Sex and BMI adjusted serum 25(OH)D levels were negatively correlated with 
age (r= -0.21; p< 0.0001). As it can be seen in Table 2, mean serum 25(OH)D 
concentration was lower at older ages. Conversely, PTH levels were higher in older 
people, and a positive correlation with age was observed (r= 0.30; p<0.0001). However, 
unlike 25(OH)D and PTH, dairy calcium intake did not significantly vary among 
different age groups.  
Table 3 shows the mean values of PTH, bone markers, BMD, and calcium intake 
for different 25(OH)D quartile groups, adjusted for  age, sex, BMI, level of education, 
exercise, alcohol use, smoking, number of chronic diseases, serum creatinine levels, and 
season of vitamin D determination. As it can be seen, mean serum PTH decreased in 
higher quartiles, and dairy calcium intake increased. No differences in both bone 
turnover markers were seen between the lowest and highest quartiles. Femoral neck and 
hip BMD values were higher in the highest serum 25(OH)D quartile than in the lowest.  
Results of the stepwise multiple linear regression analysis is showed in the Table 
4. Variables included in the model explained 21% of the variance in serum 25(OH)D 
levels in adult men and women. 
The relationship between 25(OH)D and some bone parameters is presented in 
the Figure 1. LOESS plots with 95% confidence intervals, adjusted for confounders 
show the mean values of serum PTH, BMD, and dairy calcium intake for each value of 
serum 25(OH)D. As it has been mentioned above, in the overall population, serum PTH 
was inversely correlated with 25(OH)D (unadjusted r=-0.28; p<0.0001). However, at 
serum 25(OH)D levels >30 ng/ml, this relationship became statistically non-significant, 
and a plateau in serum PTH levels was observed (Figure 1A). For the relationship 




































































exist around the serum 25(OH)D level of 30 ng/ml (Figures 1B, and 1C). Concerning 
dairy calcium intake, the threshold seems to be apparent around 25(OH)D levels of 35 
ng/ml (Figure 1 D). 
Finally, the magnitude of the difference in serum PTH levels according to 
25(OH)D quartiles, was similar in patients with different calcium intake (Figure 2). The 
lowest serum PTH levels were observed in the group with a serum 25(OH)D higher 
than 28 ng/ml, whereas the highest value was found in the group with serum 25(OH)D 
lower than 17 ng/ml. However, no statistical differences were found in adjusted PTH 




Results of this survey show that mean serum 25(OH)D concentration in 
community-dwelling postmenopausal women and adult men of our region is around 23 
ng/ml. This finding is quite similar to that reported from the UK National Diet and 
Nutrition Survey (2000-2001) of British adolescents and adults (20) and from people of 
our antipodes (New Zealand) (21), but lower than in the USA and Northern European 
population (3-6,22). We also found a low prevalence (5%) of severe vitamin D 
deficiency (serum values <10 ng/ml) but a high prevalence (40%) of vitamin D 
insufficiency (values <20 ng/ml) in postmenopausal women and adult men of our 
region. Moreover, less than 20% of our mostly independent-living middle-aged and 
older subjects had values higher than 30 ng/ml, that are considered by most authors as 
the minimum desirable serum 25(OH)D concentration (23,24). Our findings are in 
accordance with those reported from other European Mediterranean countries (2-6), and 
also with results obtained by other authors in Spain (25-33). Thus, Gomez Alonso et al. 




































































among 326 subjects of similar age (68±9 years), participating in the European Vertebral 
Osteoporosis Study (EVOS). González-Molero, et al (26) analyzed 1262 subjects aged 
20-83 years, and observed a 34% of vitamin D insufficiency (<20 ng/ml) with a mean 
25OHD values of 22.5 ng/ml. Furthermore, the prevalence of vitamin D deficiency and 
insufficiency was higher in the elderly, specially in institutionalized subjects (27,28), 
but it was also relevant in younger healthy populations (29), in postmenopausal women 
(30,31), and even in children (32). The relatively low proportion of vitamin D 
deficiency in our study would be, at least in part, due to the different methods for 
measuring 25(OH)D and to the characteristics of our population (mostly independent-
living middle aged subjects) (6,9). On the other hand, consumption of fortified foods 
has increased during the last years in our country (33), and accordingly with our results, 
recent data suggest that the prior situation of a high prevalence of vitamin D deficiency 
has improved in Spain (34). 
We found a significant seasonal difference in serum 25(OH)D levels, with the 
lowest concentrations occurring in the winter-spring and the highest during the summer-
autumn periods (20.4±7.6 ng/ml vs. 26.2±8.3 ng/ml; p<0.0001). Seasonal variations in 
serum 25OHD concentrations have been demonstrated for different populations at a 
range of latitudes (2,3,6). The present study was carried out in Camargo, a city in the 
North coast of Spain located at latitude 43ºN, with a temperate climate (average 
temperature, 14ºC), 1638 hours of sunlight per year, 1249 mm. precipitation per year, 
and were it rarely snows or freezes. Vitamin D levels were 30% higher in summer-
autumn than in the winter-spring period, a situation similar to those described 
previously in Spanish postmenopausal women (4,25,26), that reflects the differences in 
solar exposition. In fact, in our study the prevalence of vitamin D insufficiency (<20 




































































D skin synthesis in winter in latitudes above 40ºN (35,36). Nevertheless, summer/winter 
difference was much lower than differences observed several years ago in children from 
our region (32). This may reflect the higher sunshine exposition and the better response 
to cutaneous synthesis in infancy (1,2,37). On the other hand, as we have previously 
stated, higher consumption of fortified foods among Spanish adults has been described 
in recent years (33). The association between vitamin D status and dairy calcium intake 
that we observed in our population would be in accordance with this idea. Finally, the 
higher use of sunscreen during summer, especially among women, would also 
contribute to explain these findings (38,39).  
In the present study, serum 25(OH)D concentrations were higher in men than in 
women and decreased with age. Our results are again in agreement with those reported 
by other authors (3,5,6,12). Higher sunlight exposure and lower BMI in men, could 
explain at least in part, gender differences (1,6). Reasons for the decline in vitamin D 
status with age are well known and include impaired vitamin D absorption in the 
intestine and a decline in the ability of the skin to produce vitamin D3 (1,2,12,37). 
We found a significant association between low serum 25OHD levels and 
increased serum PTH and creatinine values, smoking habit, alcohol consumption, BMI, 
and increase in number of chronic diseases, as well as with low dairy calcium intake. It 
is well known that an insufficiency of vitamin D is generally associated with an increase 
in serum PTH (1,4,7), although other factors must be entertained. Thus, vitamin D 
status is also associated with renal function, and glomerular filtration rate is a major 
determinant of the PTH response to decreasing serum levels of 25(OH)D (40). Smokers 
and obese people have previously been identified as having lower levels of serum 
25(OH)D (41), and alcohol intake and number of chronic diseases have also been 
related with low levels of 25(OH)D (4,6,10). Finally, in our study, dairy calcium intake 




































































a large proportion of our subjects, hypovitaminosis D would be associated with low 
calcium intake, a situation also compatible with a relevant nutritional contribution to 
vitamin D status in our region. In our study, the magnitude of the difference in serum 
PTH according to 25(OH)D quartiles was similar among different calcium intake 
groups (Fig. 2). Steingrimsdottir et al. (11), have shown, in healthy Icelandic adults, that 
a serum 25(OH)D level >10 ng/ml would ensure adequate values of serum PTH even 
when the calcium intake level was low (<800 mg/d), while high calcium intake (>1200 
mg/d) was not sufficient to maintain ideal serum PTH levels, as long as vitamin D status 
is insufficient. Adami et al. (12), in a study conducted in Italian postmenopausal women 
with lower calcium intake and higher prevalence of vitamin D insufficiency than the 
Icelandic people, found that the effect of calcium intake on serum PTH was stronger 
and visible for all 25(OH)D levels. Calcium intake was relatively low in our sample, 
reflecting the common dietary pattern in Spain (16). However, our results are more in 
accordance with those reported by Steingrimsdottir et al. (11) than with those by Adami 
et al. (12), suggesting that vitamin D sufficiency might ensure adequate PTH values 
even when dairy calcium intake is lesser than 450 mg/d.  
We did not find a significant relationship between bone remodelling markers, 
both P1NP and -CTX, and serum 25(OH)D values. This is in disagreement with some, 
but not all, studies (4,13,35,42). Thus, Kuchuk et al. (13) found higher serum 
osteocalcin and urinary deoxypyridinoline (UDPYD) levels in older persons with lower 
serum 25(OH)D, compared with those with higher values. The same group also showed 
that serum osteocalcin and -CTX levels were significantly lower in osteoporotic 
postmenopausal women with the highest values of 25(OH)D (4). However, McDonald 
et al. (35), observed a significant association between vitamin D status and higher 
UDPYD levels, but not with serum P1NP, in postmenopausal British women. Finally, 




































































serum bone markers (P1NP and -CTX) measured by electrochemiluminiscence, in 
1734 healthy Thai individuals. Therefore, we could speculate that the characteristics of 
the population, the type of bone marker analyzed, and perhaps, some methodological 
aspects, would explain these differences. 
There are important discrepancies to define vitamin D inadequacy. Cut-offs 
indicating vitamin D insufficiency have been based on the relationship between 
25(OH)D and maximizing calcium absorption, minimizing the loss of BMD, and 
reducing the risk of falls and fractures (1,6,10). However, the majority of evidence is 
based on the concentration of 25(OH)D above which there is no further suppression of 
PTH. This approach has led to a wide range of threshold levels (4,7,8). The variability 
of these estimates may be related to the varied ethnicity and ages of the populations 
studied, varied calcium intake, presence of illness that may affect PTH concentrations, 
renal insufficiency, lack of standardization of assays for 25(OH)D, and the 
mathematical analyses used (4,8-13). Recently, the Institutes of Medicine (IOM) revised 
the recommended 25(OH)D serum levels, setting it at or above 20 ng/ml to sustain bone 
density, calcium absorption, and to minimize the risk of osteomalacia (43). However, 
the International Osteoporosis Foundation (IOF) defines 30 ng/ml as the threshold of 
25(OH)D to reduce falls and fractures (23). Such recommendation has also been 
endorsed by the US Endocrine Society [24]. In our study, adjusted LOESS plots showed 
that serum PTH reach a plateau when serum 25(OH)D was >30 ng/ml. Furthermore, 
BMD at femoral neck and total hip increased up to serum 25(OH)D levels of 30 ng/ml. 
These results suggest that, in our population, a threshold of serum 25(OH) D level of 30 
ng/ml would be necessary for the prevention of secondary hyperparathyroidism ad hip 
bone loss. This would be more in accordance with IOF and US Endocrine Society 
estimation of optimal serum 25(OH)D concentrations (23,24). Our findings would also 




































































middle-aged African American women, in which a serum concentration higher than 20 
ng/ml was necessary to prevent a rise in PTH concentrations. Kuchuk et al. (13), in 
older persons of the LASA cohort, established the optimal serum 25(OH)D in at least 20 
ng/ml, a situation that was also observed by these authors in osteoporotic 
postmenopausal women from different countries (4). Nevertheless, these authors (13) 
following a similar methodology (LOESS plots) observed a continuous decline in serum 
PTH with increasing serum 25(OH)D and no plateau, a situation that has also been 
described in some other (44), but not all (26,45) studies, using a different methodology. 
Accepting the cut-off value of 30 ng/ml, would implicate that more than 80% of 
our community-dwelling postmenopausal women and adult men would have vitamin D 
insufficiency. Therefore, instead of the increment during recent years in our country of 
available commercial dairy products supplemented with calcium and/or vitamin D, 
programs to improve vitamin D status of Spanish adult population, such as fortification 
and/or supplementation, may be required.  
Our study has several limitations. As an observational study, it is therefore 
subject to some possible bias due to confounding factors. However, adjustment for 
many potential confounding factors such as age, sex, BMI, level of education, exercise, 
alcohol use, smoking, number of chronic diseases, serum creatinine levels, and season 
of vitamin D determination, has been carried out. The study population includes 
ambulatory community-dwelling postmenopausal women and adult men recruited from 
a Primary Care Centre of our region. In our health care system, people of a certain age 
are asked to visit their family doctors regularly, at least once a year; therefore, after this 
period of time, postmenopausal women and men older than 50 are expected to have 
attended the clinic. Hence our cohort may be considered representative of the general 
community-welling population. However, because it does not include persons 




































































lower risk of hypovitaminosis D than the whole population of our region. An additional 
potential limitation is the fact that serum magnesium was not measured. Among the 
strengths we want to emphasize, it is worth mentioning that the participants were well-
characterized, and all men and postmenopausal women were carefully studied from the 
mineral and bone metabolism point of view, and excluded if any disease or treatment 
known to affect this were present. Additionally, participants on calcium and/or vitamin 
D supplements were also excluded. Finally, all samples were obtained at the same time 
of the day and in a fasting state. Thus factors to minimize biological variability were 
controlled. 
In conclusion, vitamin D insufficiency is very common among Spanish 
ambulatory community-dwelling adult people. Serum concentrations of 25(OH)D were 
lowest in the winter and highest in the summer, and decreased with age. Vitamin D 
status was also related with serum creatinine levels, smoking and alcohol use, increase 
in number of chronic diseases, low BMI and dairy calcium intake. A threshold of serum 
25(OH)D around 30 ng/ml would be necessary for the prevention of secondary 
hyperparathyroidism and hip bone loss in our population regardless of the dairy calcium 
ingestion.  Therefore, programs to improve vitamin D status of Spanish adult population 
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Tables and Figures 
 
Table 1. Baseline characteristics of the population studied.  
 
a December-April 
Distribution of PTH, P1NP, β-CTX, and number of chronic diseases was skewed, and median interquartile range 
are showed.  
25(OH)D: 25-hydroxyvitamin D; PTH: intact parathyroid hormone; P1NP: Aminoterminal propeptide of type I 
collagen ; β-CTX:  C-terminal telopeptide of type I collagen; BMD, LS: Bone mineral density at the lumbar spine; 
BMD, FN: Bone mineral density at the femoral neck; BMD, TH: Bone mineral density at the total hip. 
Parameter Total (n=1811) Men (n=657) Women (n=1154) p 
Age (yrs) 63.7±9.3 64.6±8.4 63.2±9.8 0.001 
BMI (Kg/m2) 28.9±4.4 28.8±3.4 29.0±4.8 0.49 
Dairy calcium (mg/day) 634±347 562±338 675±345 <0.0001 
Creatinine (mg/dl) 0.9±0.2 1.08±0.2 0.9±0.2 <0.0001 
25(OH)D (ng/ml) 22.6±7.9 23.5±7.7 22.1±7.9 <0.0001 
PTH (pg/ml) 51.3 40.8-64.3 51.6 40.1-63.4 51.4 41.1-64.8 0.41 
P1NP (ng/ml) 40.6 30.0-54.2 33.2 25.4-43.8 44.9 34.2-58.7 <0.0001 
β-CTX (ng/ml) 0.33 0.22-0.46 0.26 0.19-0.37 0.36 0.25-0.49 <0.0001 
BMD, LS (g/cm2) 0.960±0.153 1.019±0.154 0.927±0.142 <0.0001 
BMD, FN (g/cm2) 0.759±0.127 0.815±0.123 0.728±0.118 <0.0001 
BMD, TH (g/cm2) 0.900±0.138 0.980±0.128 0.856±0.123 <0.0001 
Education (yrs) 9.0±2.4 9.3±2.7 8.8±2.2 <0.0001 
Current Smoker (%) 14 18 12 <0.0001 
Current alcohol (%) 25 47 12 <0.0001 
Season (% winter) a 36 36 36 0.99 
No. of chronic diseases  1 0-2 1 0-2 1 0-2 0.21 
Exercise (%)     - Sedentary 
                          - Moderate 
                          - High 
2 1 3 0.01 
41 31 47 <0.0001 




































































Table 2. Levels of 25(OH)D, PTH, and dairy calcium intake according to different age 
groups. 
 
 Group n Mean±SD 






55 ± 3* 
67±5* 
80±3 




























*p<0.0001 (comparisons with the oldest group). 





































































Table 3. Differences in mean serum PTH, P1NP, and -CTX levels, BMD, and dairy 
calcium intake according to serum 25(OH)D quartiles. 
 
 
 Serum 25(OH)D (ng/ml)a 
Parameter <17 (n=462) 17-22 (n=438) 22-28 (n=480) >28 (n=431) 
25(OH)D (ng/ml) 13.4 (0.15)*** 19.6 (0.15)*** 24.9 (0.14)*** 33.2 (0.15) 
PTH     (pg/ml) 61.2 (0.9)*** 55.3 (0.9)*** 52.6 (0.8)*** 47.8 (0.9) 
P1NP    (ng/ml) 46.2 (0.9) 41.6 (0.9)** 43.4 (0.9) 45.9 (0.9) 
β-CTX (ng/ml) 0.38 (0.09) 0.33 (0.09)* 0.35 (0.09) 0.37 (0.09) 
BMD, LS (g/cm2) 0.957 (0.07) 0.959 (0.07) 0.965 (0.07) 0.958 (0.07) 
BMD, FN (g/cm2) 0.746 (0.06)* 0.758 (0.05) 0.764 (0.05) 0.770 (0.06) 
BMD, TH (g/cm2) 0.885 (0.06)** 0.894 (0.06) 0.913 (0.05) 0.913 (0.06) 
Dairy calcium (mg/day) 612 (16.7)* 610 (16.3)** 670 (15.6) 685 (16.9) 
 
Values represent mean (SE). * p<0.05 ** p<0.01 *** p<0.001, as compared to the highest quartile (>28 
ng/ml). 
 
a Adjusted for age, sex, BMI, level of education, exercise, alcohol use, smoking, number of chronic 
diseases, serum creatinine, and season of vitamin D determination.  
 
25(OH)D: 25-hydroxyvitamin D; PTH intact parathyroid hormone; P1NP: Aminoterminal propeptide of 
type I collagen ; β-CTX:  C-terminal telopeptide of type I collagen; BMD, LS: Bone mineral density at 
the lumbar spine; BMD, FN: Bone mineral density at the femoral neck; BMD, TH: Bone mineral density 





































































Table 4. Results of stepwise multiple linear regression analysis with serum 25(OH)D 
levels as dependent variable (overall sample). 
 
  β (SE) p 
Age (yr) -0.164 (0.020) <0.0001 
Sex (male) -0.058 (0.417) 0.02 
Dairy calcium intake (mg/day) 0.086 (0.001) <0.0001 
BMI (Kg/m2) -0.133 (0.040) <0.0001 
Serum PTH (pg/ml) -0.228 (0.527) <0.0001 
Winter seasona 0.184 (0.417) <0.0001 
Smoking -0.075 (0.500) 0.001 
Alcohol use -0.049 (0.423) 0.04 
No. of chronic diseases -0.086 (0.280) <0.0001 
Serum creatinine (mg/dl) -0.161 (1.071) <0.0001 
 
Dependent variable: serum 25(OH)D (ng/ml) 
a December-April 




































































Figure 1. Adjusted LOESS plots showing the relationship between serum 25(OH)D, 
and (A) PTH (p<0.001); (B) BMD at the femoral neck (p<0.01); (C)  BMD at the total 
hip (p<0.01), and (D) Dairy calcium intake (p<0.01).  
 
 
Footnote (Figure 1) 
 







Figure 2. Adjusted mean serum PTH values according to serum 25(OH)D values and 
dairy calcium intakea.  
 
Footnote (Figure 2) 
 
a Adjusted for age, sex, BMI, level of education, exercise, alcohol use, smoking, number 
of chronic diseases, serum creatinine, and season of vitamin D determination. 
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